Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

A hit deconstruction approach for the discovery of fetal hemoglobin inducers.

Benowitz AB, Eberl HC, Erickson-Miller CL, Gilmartin AG, Gore ER, Montoute MN, Wu Z.

Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3676-3680. doi: 10.1016/j.bmcl.2018.10.032. Epub 2018 Oct 22.

PMID:
30554630
2.

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.

Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, Erickson-Miller C.

J Pharmacol Exp Ther. 2017 Dec;363(3):336-347. doi: 10.1124/jpet.117.242503. Epub 2017 Sep 19.

3.

Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury.

Kapitsinou PP, Sano H, Michael M, Kobayashi H, Davidoff O, Bian A, Yao B, Zhang MZ, Harris RC, Duffy KJ, Erickson-Miller CL, Sutton TA, Haase VH.

J Clin Invest. 2014 Jun;124(6):2396-409. doi: 10.1172/JCI69073. Epub 2014 May 1.

4.

Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cells.

Li H, Xie W, Gore ER, Montoute MN, Bee WT, Zappacosta F, Zeng X, Wu Z, Kallal L, Ames RS, Pope AJ, Benowitz A, Erickson-Miller CL.

J Biomol Screen. 2013 Dec;18(10):1212-22. doi: 10.1177/1087057113499776. Epub 2013 Oct 25.

PMID:
24163393
5.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

Liesveld JL, Phillips GL 2nd, Becker M, Constine LS, Friedberg J, Andolina JR, Milner LA, DeBolt J, Smudzin T, Hyrien O, Erickson-Miller CL, Johnson BM, Dawson KL, Chen Y.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1745-52. doi: 10.1016/j.bbmt.2013.10.002. Epub 2013 Oct 8.

6.

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.

Erickson-Miller CL, Pillarisetti K, Kirchner J, Figueroa DJ, Ottesen L, Martin AM, Liu Y, Kamel YM, Messam C.

BMC Cancer. 2012 Sep 11;12:405. doi: 10.1186/1471-2407-12-405.

7.

Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury.

Kapitsinou PP, Jaffe J, Michael M, Swan CE, Duffy KJ, Erickson-Miller CL, Haase VH.

Am J Physiol Renal Physiol. 2012 May 1;302(9):F1172-9. doi: 10.1152/ajprenal.00667.2011. Epub 2012 Jan 18.

8.

Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site.

Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, Galbraith S, Ho T, Zhang H, Hong X, Ward P, Hofmann G, Siegfried B, Zappacosta F, Washio Y, Cao P, Qu J, Bertrand S, Wang DY, Head MS, Li H, Moores S, Lai Z, Johanson K, Burton G, Erickson-Miller C, Simpson G, Tummino P, Copeland RA, Oliff A.

Chem Biol. 2011 Feb 25;18(2):177-86. doi: 10.1016/j.chembiol.2010.12.013.

9.

Thrombopoietin receptor levels in tumor cell lines and primary tumors.

Erickson-Miller CL, Chadderton A, Gibbard A, Kirchner J, Pillarisetti K, Baker K, Pandite L, El-Hariry I, Mostafa Kamel Y, Liu Y, Martin AM, Messam C.

J Oncol. 2010;2010:135354. doi: 10.1155/2010/135354. Epub 2010 Dec 28.

10.

Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.

Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN.

J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. doi: 10.1097/FJC.0b013e3181e2bfef.

PMID:
20714241
11.

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.

Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL, Haase VH.

Blood. 2010 Oct 21;116(16):3039-48. doi: 10.1182/blood-2010-02-270322. Epub 2010 Jul 13.

12.

Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.

Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A.

Leuk Res. 2010 Sep;34(9):1224-31. doi: 10.1016/j.leukres.2010.02.005. Epub 2010 Mar 3.

PMID:
20202683
13.

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Blood. 2009 Oct 29;114(18):3899-908. doi: 10.1182/blood-2009-04-219493. Epub 2009 Aug 26.

14.

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR.

Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24.

PMID:
19631713
15.

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM.

Stem Cells. 2009 Feb;27(2):424-30. doi: 10.1634/stemcells.2008-0366.

16.

DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.

Bogacheva O, Bogachev O, Menon M, Dev A, Houde E, Valoret EI, Prosser HM, Creasy CL, Pickering SJ, Grau E, Rance K, Livi GP, Karur V, Erickson-Miller CL, Wojchowski DM.

J Biol Chem. 2008 Dec 26;283(52):36665-75. doi: 10.1074/jbc.M807844200. Epub 2008 Oct 14.

17.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL.

Blood. 2007 Jun 1;109(11):4739-41. Epub 2007 Feb 27.

18.

New benzimidazoles as thrombopoietin receptor agonists.

Safonov IG, Heerding DA, Keenan RM, Price AT, Erickson-Miller CL, Hopson CB, Levin JL, Lord KA, Tapley PM.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1212-6. Epub 2006 Jan 11.

PMID:
16376078
19.

Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects.

Prabhakar U, Conway TM, Murdock P, Mooney JL, Clark S, Hedge P, Bond BC, Jazwinska EC, Barnes MR, Tobin F, Damian-Iordachi V, Greller L, Hurle M, Stubbs AP, Li Z, Valoret EI, Erickson-Miller C, Cass L, Levitt B, Davis HM, Jorkasky DK, Williams WV.

DNA Cell Biol. 2005 Jul;24(7):410-31.

PMID:
16008510
20.

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.

Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, Valoret EI, Duffy KJ, Luengo JL, Rosen J, Miller SG, Dillon SB, Lamb P.

Exp Hematol. 2005 Jan;33(1):85-93.

PMID:
15661401
21.

DYRK gene structure and erythroid-restricted features of DYRK3 gene expression.

Zhang D, Li K, Erickson-Miller CL, Weiss M, Wojchowski DM.

Genomics. 2005 Jan;85(1):117-30.

PMID:
15607427
22.

Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.

Virgo P, Denning-Kendall PA, Erickson-Miller CL, Singha S, Evely R, Hows JM, Freeman SD.

Br J Haematol. 2003 Nov;123(3):420-30.

PMID:
14617000
23.

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

Erickson-Miller CL, Freeman SD, Hopson CB, D'Alessio KJ, Fischer EI, Kikly KK, Abrahamson JA, Holmes SD, King AG.

Exp Hematol. 2003 May;31(5):382-8.

PMID:
12763136
24.

Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics.

Duffy KJ, Price AT, Delorme E, Dillon SB, Duquenne C, Erickson-Miller C, Giampa L, Huang Y, Keenan RM, Lamb P, Liu N, Miller SG, Rosen J, Shaw AN, Smith H, Wiggall KJ, Zhang L, Luengo JI.

J Med Chem. 2002 Aug 15;45(17):3576-8.

PMID:
12166929
25.

Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics.

Duffy KJ, Shaw AN, Delorme E, Dillon SB, Erickson-Miller C, Giampa L, Huang Y, Keenan RM, Lamb P, Liu N, Miller SG, Price AT, Rosen J, Smith H, Wiggall KJ, Zhang L, Luengo JI.

J Med Chem. 2002 Aug 15;45(17):3573-5.

PMID:
12166928
26.
27.

Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis.

Duffy KJ, Darcy MG, Delorme E, Dillon SB, Eppley DF, Erickson-Miller C, Giampa L, Hopson CB, Huang Y, Keenan RM, Lamb P, Leong L, Liu N, Miller SG, Price AT, Rosen J, Shah R, Shaw TN, Smith H, Stark KC, Tian SS, Tyree C, Wiggall KJ, Zhang L, Luengo JI.

J Med Chem. 2001 Oct 25;44(22):3730-45.

PMID:
11606138
28.
29.
30.

Evaluating energetics of erythropoietin ligand binding to homodimerized receptor extracellular domains.

Hensley P, Doyle ML, Myszka DG, Woody RW, Brigham-Burke MR, Erickson-Miller CL, Griffin CA, Jones CS, McNulty DE, O'Brien SP, Amegadzie BY, MacKenzie L, Ryan MD, Young PR.

Methods Enzymol. 2000;323:177-207. No abstract available.

PMID:
10944753
31.

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils.

Kikly KK, Bochner BS, Freeman SD, Tan KB, Gallagher KT, D'alessio KJ, Holmes SD, Abrahamson JA, Erickson-Miller CL, Murdock PR, Tachimoto H, Schleimer RP, White JR.

J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1093-100.

PMID:
10856141
32.
33.
34.

Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro.

Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, Parchment RE.

Cancer Chemother Pharmacol. 1997;39(5):467-72.

PMID:
9054963
35.

HIMeg-1, a cell line derived from a CML patient, is capable of monocytic and megakaryocytic differentiation.

Cheng T, Erickson-Miller CL, Li C, Cardier J, Wang Y, Dempsey J, Mogle M, Barbera E, Murphy MJ Jr, Dai W.

Leukemia. 1995 Jul;9(7):1257-63.

PMID:
7543177
36.

In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow.

Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ Jr, Grieshaber CK.

J Natl Cancer Inst. 1994 Feb 16;86(4):273-80.

PMID:
8158681
37.

Megakaryocytopoiesis and platelet production: does stem cell factor play a role?

Erickson-Miller CL, Ji H, Murphy MJ Jr.

Stem Cells. 1993 Jul;11 Suppl 2:163-9.

PMID:
7691322
38.

Megakaryocyte colony-stimulating factor (Meg-CSF) is a unique cytokine specific for the megakaryocyte lineage.

Erickson-Miller CL, Ji H, Parchment RE, Murphy MJ Jr.

Br J Haematol. 1993 Jun;84(2):197-203.

PMID:
8398818
39.

Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning.

Parchment RE, Huang M, Erickson-Miller CL.

Toxicol Pathol. 1993;21(2):241-50.

PMID:
8210945
40.

Effects of recombinant cytokines on murine megakaryocyte colony formation in a serum-free fibrin clot culture system.

Ogata K, Erickson-Miller CL, Nomura T, Abe K, Zhang Z, Murphy MJ Jr.

Pathobiology. 1992;60(3):143-8.

PMID:
1627259
41.
42.

Purification of GCT cell-derived human colony-stimulating factors.

Erickson-Miller CL, Abboud CN, Brennan JK.

Exp Hematol. 1988 Mar;16(3):184-9.

PMID:
2448161
43.

Macrophage colony-stimulating factor in nerve growth factor preparations.

Erickson-Miller CL, Abboud CN, Stach RW, Frantz CN, Brennan JK.

J Neurosci Res. 1988;19(1):52-6.

PMID:
3257797
44.

Interactions of dimethyl sulfoxide and granulocyte-macrophage colony-stimulating factors on the growth and maturation of HL-60 cells.

Brennan JK, Lee KS, Abboud CN, Erickson-Miller CL, Keng PC.

J Cell Physiol. 1987 Aug;132(2):246-54.

PMID:
3497928

Supplemental Content

Loading ...
Support Center